Celadon Pharmaceuticals Regulatory News (CEL)

1 Mar 2005 07:01

Celsis International PLC01 March 2005 CELSIS INTERNATIONAL PLC Non-Executive Director Change 1 March 2005: Celsis International plc ("Celsis" or the "Company"), themicrobial detection and analytical services company, today announces that DrPeter Grant will stand down as non-executive director of the Board withimmediate effect. Dr Grant leaves Celsis to pursue his career as OperationsDirector of the recently floated Biofusion plc. He has served as non-executivedirector of the Company since May 2002, prior to this he was an executivedirector since Celsis floated on the London Stock Exchange in 1993. Jack Rowell, Non-Executive Chairman of Celsis, commented: "We are extremely grateful to Peter for the significant contribution he has madeto the formation and development of Celsis, both in his capacity of executiveand non-executive director, over the last 12 years. As a founding director ofCelsis, Dr Grant was responsible for developing the technology base from conceptto product and was instrumental in growing Celsis into the successful companythat it is today. On behalf of the Board we wish Peter well in his futurecareer and thank him for his commitment to Celsis." Enquiries: Celsis International plc Tel: 01638 600 151Jay LeCoque, Chief Executive OfficerJenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113Ben AtwellLucy Briggs Notes to editors Celsis International plc Celsis International plc is a microbial detection and analytical servicescompany operating through two divisions, the Product Group and the LaboratoryGroup. Using its proprietary enzyme technology, the Product Group is the world leaderin the provision of diagnostic systems for the rapid detection of microbialcontamination. It works in close collaboration with many of the world's leadingpharmaceutical, personal care and beverage companies, ensuring the safety andquality of products bound for consumers. The Laboratory Group providesoutsourced analytical testing services to pharmaceutical companies to ensure thestability and chemical composition of their products. In addition to ensuring product quality and safety for consumers, both divisionshave the capacity to deliver substantial cost savings to Celsis' customers. Byreducing the time it takes to test and release raw materials and finished goodsto the market place, Celsis' products facilitate increased manufacturingproductivity and improved supply chain management. Celsis International plc is listed on the London Stock Exchange (CEL.L).Further information can be found on the Company's website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange